The value of tumor markers in evaluating chemotherapy response and prognosis in chinese patients with advanced non-small cell lung cancer

Chemotherapy

Volumn 56, Issue 6, 2010, Pages 417-423

  Jin, Bo ^a   Huang, Ai Mi ^a   Zhong, Run Bo ^a   Han, Bao Hui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Advanced non small cell lung cancer; Carcinoembryonic antigen; CYFRA21 1; Neuron specific enolase

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CISPLATIN; CYTOKERATIN 19 FRAGMENT; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; NAVELBINE; NEURON SPECIFIC ENOLASE; PACLITAXEL; TUMOR MARKER;

ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CHINESE; CONTINUOUS INFUSION; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; KERATIN-19; LUNG NEOPLASMS; MALE; MIDDLE AGED; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 78149454599     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000317580     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
2. Ramalingam S, Belani CP: State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 2004; 31: 68-74
3. Xiong X, Liu H, Fu L, Li L, Li J, Luo X, Mei C: Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines. Chemotherapy 2008; 54: 463-474
4. Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F: Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines. Chemotherapy 2008; 54: 166-175
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, Somerfield MR, American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353
6. Lieberman R: Evidence-based medical perspectives: the evolving role of PSA for early detection, monitoring of treatment response, and as a surrogate end point of efficacy for interventions in men with different clinical risk states for the prevention and progression of prostate cancer. Am J Ther 2004; 11: 501-506
7. Meyer T, Rustin GJS: Role of tumor markers in monitoring epithelial ovarian cancer. Br J Cancer 2000; 82: 1535-1538
8. Brundage MD, Davies D, Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-1057
9. Trape J, Buxo J, Perez de Olaguer J, Vidal C: Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 2003; 23: 4277-4281
10. Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S: Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol Rep 2003; 10: 475-482
11. Pujol JL, Molinier O, Ebert W, Daurès JP, Barlesi F, Buccheri G, Paesmans M, Quoix E, Moro-Sibilot D, Szturmowicz M, Bréchot JM, Muley T, Grenier J: CYFRA21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90: 2097-2105 (Pubitemid 38869712)
12. Muley T, Dienemann H, Ebert W: CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 2004; 24: 1953-1956
13. Barlési F, Gimenez C, Torre JP, Doddoli C, Mancini J, Greillier L, Roux F, Kleisbauer JP: Prognostic value of combination of Cyfra 21- 1, CEA and NSE in patients with advanced non-small-cell lung cancer. Respir Med 2004; 98: 357-362
14. Molina R, Filella X, Augé JM, Fuentes R, Bover I, Rifa J, Moreno V, Canals E, Viñolas N, Marquez A, Barreiro E, Borras J, Viladiu P: Tumor markers (CEA, CA 125, CYFRA 21- 1, SCC and NSE) in patients with non-smallcell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumor Biol 2003; 24: 209-218
15. Lee JH, Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005; 128: 2298-2303
16. Reinmuth N, Brandt B, Semik M, Kunze WP, Achatzy R, Scheld HH, Broermann P, Berdel WE, Macha HN, Thomas M: Prognostic impact of CYFRA21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer 2002; 36: 265-270
17. Diez M, Torres A, Ortega L, Maestro M, Hernando F, Gomez A, Picardo A, Granell J, Balibrea JL: Value of serum neuron-specific enolase in nonsmall cell lung cancer. Oncology 1993; 50: 127-131
18. Van Zandwijk N, Jassem E, Bonfrer JMG, Mooi WJ, van Tinteren H: Serum neuro-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small cell lung cancer. Semin Oncol 1992; 19: 37-43
19. Kleisbauer JP, Castelnau O, Thomas P, Ramirez J, Lanteaume A, Roux F: Prognostic value of pre-therapeutic levels of carcinoembryonic antigen in primary bronchial carcinoma. Bull Cancer 1995; 82: 1019-1024
20. American Thoracic Society and European Respiratory Society: Pretreatment evaluation of non-small cell lung cancer. Am Rev Respir Crit Care Med 1997; 156: 320-332
21. Sawabata N, Ohta M, Takeda S, Hirano H, Okumura Y, Asada H, Maeda H: Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with nonsmall cell lung cancer. Ann Thorac Surg 2002; 74: 174-179
22. Vollmer RT, Govindan R, Graziano SL, Gamble G, Garst J, Kelley MJ, Christenson RH: Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003; 9: 1728-1733
23. Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D: Circulating nucleosomes predict the response to chemotherapy in patients with advanced nonsmall cell lung cancer. Clin Cancer Res 2004; 10: 5981-5987
24. Holdenrieder S, Stieber P, VON Pawel J, Raith H, Nagel D, Feldmann K, Seidel D: Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin- 19 fragments. Ann NY Acad Sci 2006; 1075: 244-257
25. Merle P, Janicot H, Filaire M, Roux D, Bailly C, Vincent C, Gachon F, Tchirkov A, Kwiatkowski F, Naamé A, Escande G, Caillaud D, Verrelle P: Early CYFRA21-1 variation predicts tumor response to chemotherapy and survival in locally advanced non-small cell lung cancer patients. Int J Biol Markers 2004; 19: 310-315
26. Chiu CH, Shih YN, Tsai CM, Liou JL, Chen YM, Perng RP: Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib. Lung Cancer 2007; 57: 213-221
27. Pujol JL, Quantin X, Jacot W, Boher JM, Grenier J, Lamy PJ: Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 2003; 39: 131-138
28. Schneider J, Philipp M, Salewski L, Velcovsky HG: Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab 2003; 49: 35-42
29. Wójcik E, Kulpa JK, Sas-Korczyñska B, Korzeniowski S, Jakubowicz J: ProGRP and NSE in therapy monitoring in patients with small cell lung cancer. Anticancer Res 2008; 28: 3027-3033
30. Weber WA, Petersen V, Schmidt B, Tyndale- Hines L, Link T, Peschel C, Schwaiger M: Positron emission tomography in nonsmall- cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21: 2651-2657
31. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD: [18F] Fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-1143